Welcome to our dedicated page for Geovax Labs news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on Geovax Labs stock.
GeoVax Labs, Inc. (GOVX) is a clinical-stage biotechnology company whose news flow centers on vaccines for infectious diseases and therapies for solid tumor cancers. Company press releases describe active clinical development of GEO-CM04S1, a next-generation COVID-19 vaccine, and Gedeptin®, a gene-directed oncolytic therapy for head and neck cancers, along with additional programs such as the GEO-MVA Mpox/Smallpox vaccine candidate and MVA-VLP-based cancer immunotherapies.
Investors following GEO-CM04S1 news will see updates on Phase 2 trials in immunocompromised patients, chronic lymphocytic leukemia (CLL) patients, and healthy adults, as well as progress on a BARDA-funded 10,000-participant Phase 2b trial comparing GEO-CM04S1 with an approved COVID-19 vaccine. News items also cover interim data reviews, such as immune response outcomes in CLL booster studies, and broader context on the role of dual-antigen MVA-based vaccines in populations with limited responses to existing vaccines.
Oncology-related news highlights Gedeptin’s completed multicenter Phase 1/2 trial in advanced head and neck cancers and plans for a Phase 2 trial in first recurrent head and neck cancer in combination with an immune checkpoint inhibitor. Additional releases discuss preclinical data and intellectual property developments for candidates like MVA-VLP-MUC1, as well as participation in conferences and panel discussions on innovative therapies for solid tumors.
GeoVax news also includes corporate and financial updates, such as registered direct offerings and private placements of common stock and warrants, government contract revenues tied to the BARDA/Project NextGen award, and quarterly financial results. For investors and observers, the GOVX news stream provides insight into clinical milestones, regulatory and funding developments, patent allowances, and corporate presentations. Bookmarking this page allows readers to monitor how GeoVax’s vaccine and immuno-oncology programs progress through clinical stages and financing events over time.
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines, will present at the Emerging Growth Conference on August 21, 2024. Chairman and CEO David Dodd will deliver a live, interactive presentation at 4:10pm ET, discussing recent Mpox developments and milestones related to the BARDA Project NextGen Award for their next-generation COVID-19 vaccine.
The event offers shareholders and investors the opportunity to interact with Mr. Dodd in real-time. Attendees can submit questions in advance or during the event. Registration is required to attend and receive updates. For those unable to join live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.
GeoVax Labs, Inc. (Nasdaq: GOVX) has appointed Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Prof. Lambe, a renowned vaccinology and immunology expert from the Oxford Vaccine Group, was a key figure in developing the Oxford/AstraZeneca COVID-19 vaccine. Her research focuses on designing vaccination strategies based on post-infection immune responses. GeoVax's Chief Scientific Officer, Dr. Mark Newman, highlighted how Prof. Lambe's expertise aligns with their vaccine and immunotherapy programs, including the recent BARDA Project NextGen Award for next-generation COVID-19 vaccines. David Dodd, GeoVax's Chairman and CEO, emphasized the importance of Prof. Lambe's insights for advancing their clinical trials and bringing new therapies to market.
GeoVax Labs, Inc. (Nasdaq: GOVX) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. Awarded BARDA Project NextGen (PNG) contract worth over $350 million to advance GEO-CM04S1, their next-generation COVID-19 vaccine, into a 10,000-participant Phase 2b study.
2. Partnered with Allucent, a global CRO, to conduct the Phase 2b trial.
3. Advancing Gedeptin® into an expanded Phase 2 clinical trial for first-recurrence head and neck cancer, with activation expected in H1 2025.
4. Produced first lot of GEO-CM04S1 with a commercial manufacturing platform.
5. Q2 2024 net loss of $5,064,042 ($1.99 per share), compared to $5,927,620 ($3.79 per share) in Q2 2023.
6. Cash balance of $1,561,712 as of June 30, 2024.
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced plans for a Phase 2 trial of its Gedeptin® cancer therapy following a clinical advisory committee review. The trial will focus on first-recurrence head and neck cancer, combining Gedeptin with an immune checkpoint inhibitor. This decision comes after reviewing the completed PNP-002 Phase 1b/2a and PNP-001 Phase 1 trials, which demonstrated acceptable safety and efficacy in advanced head and neck squamous cell carcinoma (HNSCC) patients.
The planned Phase 2 trial aims to establish the efficacy of neoadjuvant Gedeptin therapy combined with an immune checkpoint inhibitor. It will involve approximately 6 patients, with pathologic response rate as the primary endpoint. GeoVax anticipates trial activation during the first half of 2025. The company is also pursuing development plans for Gedeptin in additional solid tumor indications in partnership with leading academic oncology centers.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases, has announced it will release its second quarter 2024 financial results on Tuesday, August 6, 2024, after U.S. markets close. The company will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results and provide a corporate update.
Investors and interested parties can join the conference call using the following details:
- Domestic: (800) 715-9871
- International: +1 (646) 307-1963
- Conference ID: 3852178
A webcast of the call will be available at https://edge.media-server.com/mmc/p/qj3e68n8, with a replay accessible for three months after the event.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.